

## Curriculum Vitae

DATI PERSONALI	
Nome	Cristina Clissa, MD, PhD
Anno di nascita	1979
Cittadinanza	Italiana
Indirizzo lavorativo	AOUI Azienda Ospedaliera Universitaria Integrata di Verona, Policlinico G.B. Rossi, Unità Operativa Complessa di Ematologia e Centro Trapianto Midollo Osseo, Piazzale L.A. Scuro 10, 37134 Verona
lingua	Italiano, Inglese scritto e parlato

FORMAZIONE			
06/GIU/2013	Dottorato di Ricerca in Ematologia Clinica e Sperimentale ed Ematopatologia	Università Alma Mater Studiorum	Bologna, Italia
03/NOV/2009	Specializzazione in Ematologia (voto 70/70 e Lode)	Università Alma Mater Studiorum	Bologna, Italia
21/FEB/2005	Abilitazione all'esercizio della professione medica (n° 4406)	Università Gabriele D'Annunzio	Chieti, Italia
27/OCT/2004	Laurea in Medicina (voto 110/110 e Lode)	Università Gabriele D'Annunzio	Chieti, Italia
1998	Diploma di maturità Scientifica	Raffaele Mattioli	Vasto (CH) Italia

ESPERIENZA CLINICA E DI RICERCA	
15/02/2021- ongoing	<b>Dirigente medico di I livello</b> presso UOC Ematologia e Centro Trapianti, AOUI Azienda ospedaliera Universitaria Integrata Verona
Gen 2020 – 14 feb 2021	<b>Dirigente Medico di I livello</b> presso UOC Ematologia e Centro Trapianti, AORMN Marche Nord Pesaro, Italia (Dr. Giuseppe Visani)
ago 2014-dic 2019	<b>Gestione di trials clinici (Sub-Investigator)</b> fase I-II-III UOC Ematologia e Centro Trapianti, AORMN Marche Nord Pesaro, Italia (Dr. Giuseppe Visani)
2013-2014	<b>Ricercatore</b> Istituto di Ematologia “L.&A. Seràgnoli” DIMES Università Alma Mater Studiorum, Bologna Italia (Prof. Michele Cavo, Prof. Giovanni Martinelli)
AA 2009/2010-2012/2013	<b>Dottorato di ricerca in Ematologia</b> Istituto di Ematologia “L.&A. Seragnoli” DIMES Università Alma Mater Studiorum, Bologna Italia (Prof. Stefano Pileri, tutor Dr. Carlo Finelli)
AA 2005/2006- 2008/2009	<b>Scuola di Specializzazione in Ematologia</b> Istituto di Ematologia “L.&A. Seràgnoli” DIMES Università Alma Mater Studiorum, Bologna Italia (Prof. Michele Baccarani , tutor Dr. Carlo Finelli)
2004-2005	<b>Medico volontario</b> Ce.S.I. (Centro Studi Scienze dell'Invecchiamento) Università Gabriele D'Annunzio, Chieti Italia (Prof. Davì Giovanni)
2004-2005	<b>Medico interno volontario</b> Centro regionale Malattie Rare del Sangue e della Coagulazione Ospedale S. Spirito di Pescara (Dr. Alfredo Dragani)

ESPERIENZA LAVORATIVA
-----------------------

15/02/2021- ongoing	Dirigente medico di I livello presso UOC Ematologia e Centro Trapianti, AOUI Azienda Ospedaliera Universitaria Integrata Verona
Gen 2020-14/02/2021	Dirigente medico di I livello UOC Ematologia e Centro Trapianti, AORMN Marche Nord Pesaro, Italia (Dr. Giuseppe Visani)
01/08/2016-31/12/2019	Dirigente medico con contratto libero professionale, in regime di convenzione con il SSN, presso l'UOC di Ematologia e Centro Trapianti Cellule Staminali Emopoietiche, AORMN Marche Nord Pesaro, Italia
01/08/2014-31/07/2016	Dirigente medico con contratto di collaborazione a progetto, in regime di convenzione con il SSN, presso l'UOC di Ematologia e Centro Trapianti Cellule Staminali Emopoietiche, AORMN Marche Nord Pesaro, Italia
01/11/2010-31/07/2014	Medico specialista con contratto libero professionale, in regime di convenzione con il SSN, presso il Servizio di Assistenza Domiciliare Ematologica BolognAIL per pazienti afferenti all'Istituto di Ematologia "L.&A. Seràgnoli" Policlinico Sant'Orsola-Malpighi di Bologna

#### SOCIETA' SCIENTIFICHE

Membro della :

- Società Italiana di Ematologia (SIE) dal 2007
- Società italiana di Ematologia Sperimentale (SIES) dal 2008
- European Hematology Association (EHA) dal 2012
- Federazione Italiana Sindromi Mielodisplastiche (FISiM) dal 2020

#### AMBITI D'INTERESSE

- Sindromi mielodisplastiche
- Trombocitopenia Immune primaria
- Mieloma multiplo e malattie plasmacellulari
- Leucemia Acuta Mieloide
- Trapianto Allogeneico di cellule staminali emopoietiche
- Emoglobinuria parossistica notturna e malattie del complemento
- Aplasia ed ipoplasie midollari
- Emostasi e malattie della coagulazione
- Infezioni in ematologia

#### PUBBLICAZIONI

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. Sandra Mossuto, Enrico Attardi, Francesco Alesiani, et al. Hemasphere. 2020 Oct; 4(5): e483. Published online 2020 Sep 23. doi: 10.1097/HS9.0000000000000483

ITP management in real life. Vianelli N, Bellio L, Baldacci E, Buccisano F, Carrai V, Clissa C, Esposito D, Giuffrida G, Magro D, Podda G, Rivolti E. Medicina X Ematologi. Novembre 2018.

Single shot medium dose melphalan in resistant/relapsed myeloma: a bridge to target therapies? Clissa C, Loscocco F, Isidori A, Barulli S, Malerba L, Guiducci B, Visani G. Trends in Transplantation, 2018 Jul 20. Volume 11(2):1-2. Doi:10.15761/TiT.1000248.

High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Tsang ES, Villa D, Loscocco F, Visani G, Power M, Guiducci



B, Clissa C, Song K, Toze C, Abou Mourad Y, Sutherland H, Sanford D, Nantel SH, Sehn LH, Scott DW, Savage KJ, Connors JM, Gerrie AS, Isidori A. Bone Marrow Transplant. 2018 Aug 31. doi: 10.1038/s41409-018-0328-9.

Nuclear translocation of PKC- $\alpha$  is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). Poli A, Ratti S, Finelli C, Mongiorgi S, Clissa C, Lonetti A, Cappellini A, Catozzi A, Barraco M, Suh PG, Manzoli L, McCubrey JA, Cocco L, Follo MY. FASEB J. 2018 Feb;32(2):681-692. doi: 10.1096/fj.201700690R. Epub 2018 Jan 4.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. Finelli C, Follo MY, Stanzani M, Parisi S, Clissa C, Mongiorgi S, Barraco M, Cocco L. Curr Pharm Des. 2016;22(16):2349-57.

Enteric-coated mycophenolate sodium: a new option for GHVD prophylaxis? Isidori A, Loscocco F, Malerba L, Clissa C, Guiducci B, Visani G. Eur J Haematol. 2017 Apr;98(4):320-321. doi: 10.1111/ejh.12739.

Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. Mongiorgi S, Finelli C, Yang YR, Clissa C, McCubrey JA, Billi AM, Manzoli L, Suh PG, Cocco L, Follo MY. Expert Opin Ther Targets. 2016 Jun;20(6):677-87. doi: 10.1517/14728222.2016.1125885. Epub 2015 Dec 17. Review.

PBSC mobilization in patients with autoimmune diseases: what's next. Isidori A, Loscocco F, Guiducci B, Malerba L, Clissa C, Visani G. Eur J Haematol. 2016 Jul;97(1):5-6. doi: 10.1111/ejh.12701. No abstract available.

Advancement in high dose therapy and autologous stem cell rescue in lymphoma. Isidori A, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, Visani G. World J Stem Cells. 2015 Aug 26;7(7):1039-46. doi: 10.4252/wjsc.v7.i7.1039. Review

An increased expression of PI-PLC $\beta$ 1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes. , Cocco L, Mongiorgi S, , Russo D, Bosi C, Quaranta M, Malagola M, Parisi S, Stanzani M, Ramazzotti G, Mariani GA, Billi AM, Manzoli L, Follo MY. J Leukoc Biol 2015 May 14.

Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy. Manzoli L, Mongiorgi S, Clissa C, Finelli C, Billi AM, Poli A, Quaranta M, Cocco L, Follo MY. Mini Rev Med Chem. 2014 Oct 13.

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Isidori A, Salvestrini V, Ciciarello M, Loscocco F, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A. Expert Rev Hematol. 2014 Dec;7(6):807-18.

The role of iron metabolism in myelodysplastic syndromes. Finelli C, Clissa C, Stanzani M. Recenti Prog Med. 2014 Mar;105(3):123-6. doi: 10.1701/1434.15874. Italian.

Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering". Martinelli G, Sartor C, Papayannidis C, Iacobucci I, Paolini S, Clissa C, Ottaviani E, Finelli C. Recenti Prog Med. 2014 Mar;105(3):118-22. doi: 10.1701/1434.15873. Italian.

Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes. Fili C, Malagola M, Follo MY, Finelli C, Iacobucci I, Martinelli G, Cattina F, Clissa C, Candoni A, Fanin R, Gobbi M, Bocchia M, Defina M, Spedini P, Skert C, Manzoli L, Cocco L, Russo D. Clin Cancer Res. 2013 May 22.



Nuclear PI-PLC  $\beta 1$  and Myelodysplastic syndromes: from bench to clinics. Mongiorgi S, Follo MY, Clissa C, Giardino R, Fini M, Manzoli L, Ramazzotti G, Fiume R, Finelli C, Cocco L. *Curr Top Microbiol Immunol*. 2012;362:235-45.

Quality of life and physicians' perception in myelodysplastic syndromes. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. *Am J Blood Res*. 2012;2(2):136-47.

Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Follo MY, Mongiorgi S, Clissa C, Paolini S, Martinelli G, Martelli AM, Fioravanti G, Manzoli L, Finelli C, Cocco L. *Leukemia*. 2012 Dec;26(12):2474-82. doi: 10.1038/leu.2012.133.

Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Stanzani M, Battista G, Sassi C, Lewis RE, Tolomelli G, Clissa C, Femia R, Bazzocchi A, Tumietto F, Viale P, Ambretti S, Baccarani M, Vianelli N. *Clin Infect Dis*. 2012 Mar 1;54(5):610-6. doi: 10.1093/cid/cir861.

Epigenetic regulation of nuclear PI-PLC $\beta 1$  signaling pathway in low-risk MDS patients during azacitidine treatment. Follo MY, Russo D, Finelli C, Mongiorgi S, Clissa C, Filì C, Colombi C, Gobbi M, Manzoli L, Piazzini M, Martelli AM, Cocco L. *Leukemia*. 2012 May;26(5):943-50. doi: 10.1038/leu.2011.300.

Synergistic induction of PI-PLC $\beta 1$  signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, Paolini S, Martinelli G, Martelli AM, Cocco L. *Leukemia*. 2011 Feb;25(2):271-80. doi: 10.1038/leu.2010.266.

Nuclear inositide signaling in myelodysplastic syndromes. Follo MY, Mongiorgi S, Finelli C, Clissa C, Ramazzotti G, Fiume R, Faenza I, Manzoli L, Martelli AM, Cocco L. *J Cell Biochem*. 2010 Apr 15;109(6):1065-71.

Reduction of phosphoinositide-phospholipase C  $\beta 1$  methylation predicts the responsiveness to azacitidine in high-risk MDS. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, Chiarini F, Ramazzotti G, Baccarani M, Martelli AM, Manzoli L, Martinelli G, Cocco L. *Proc Natl Acad Sci U S A*. 2009 Sep 29;106(39):16811-6.

Phosphoinositide-phospholipase C  $\beta 1$  mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C, Martinelli G, Baccarani M, Manzoli L, Martelli AM, Cocco L. *J Clin Oncol*. 2009 Feb 10;27(5):782-90.

PKR is activated in MDS patients and its subcellular localization depends on disease severity. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, Blalock WL, Cocco L, Martelli AM. *Leukemia*. 2008 Dec;22(12):2267-9.

Soluble RAGE in type 2 diabetes: association with oxidative stress. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattini G, Consoli A, Davì G. *Free Radic Biol Med*. 2007 Aug 15;43(4):511-8.

Tesi di Dottorato di ricerca in Ematologia Clinica, Sperimentale ed Ematopatologia. "La terapia demetilante con 5-Azacitidina nelle Sindromi Mielodisplastiche: esperienza clinica del Nostro Istituto e correlazione



con i dati biologici". 6 Giugno 2013

The myelodysplastic syndromes: diagnosis, prognosis and therapy. Clissa C, Finelli C, De Vivo A. Italian Journal of Medicine 2010;4(2) Speciale:3-4

Co-author of the book "Myelodysplastic Syndromes: from theory to clinical practice", Elsevier Masson 1° edition 2007

Co-author of the book "Myelodysplastic Syndromes: from theory to clinical practice", Elsevier Masson 2° edition 2010

CONGRESSI IN QUALITÀ DI RELATORE	
2021	29 giu Gestione regionale della ITP e nuove terapie disponibili (webinar)
2021	22 giu Trombocitopenia Immune Primaria (webinar)
2021	25 mag Ruolo del carfilzomib nella gestione del paziente ricaduto refrattario con Mieloma multiplo (webinar)
2021	21 apr Ottimizzazione dell'approccio diagnostico e terapeutico nel mieloma multiplo (webinar)
2020	26 ott Porpora trombotica trombocitopenica, sindrome emolitico-uremica atipica ed emoglobinuria parossistica notturna: zone in comune tra diagnosi e terapia? (Pesaro stage, webinar)
2019	28 oct: Venocclusive disease (VOD): diagnosi e terapia (Pesaro, Italy)
2019	9 jul: Quali novità in ITP (Ancona, Italy)
2019	09-11 may: AML Rising Star Program (Windsor, London UK)
2018	05 nov: Stage PhotoHematology 2018 "PNH e HUSa: diagnosis and therapy" (Pesaro, Italy)
2018	24 oct: Immune thrombocytopenia management in real life. Editorial project (Milan, Italy)
2018	26 sept: Paroxistic Nocturnal Hemoglobinuria 2018 (Ancona, Italy)
2018	21 sept: Preceptorship La gestione del paziente con Leucemia Linfatica Cronica e Linfoma follicolare (Pesaro, Italy)
2018	10 sep: Non Hodgkin Lymphoma between biosimilars and new drugs, "Monoclonal antibody antiCD20 in Non Hodgkin Indolent Lymphoma" (Pesaro, Italy)
2018	22 jun: Immune thrombocytopenia: focus on diagnostic pathways and critical issues. Panel discussion (Pescara, Italy)
2017	07 nov: Stage La Quadreria dell'Ematologia, "Acute myeloid leukemia of the elderly: from old standard to new therapies" (Pesaro, Italy)
2017	08 jun: Lymphoproliferative syndromes and infections. Multidisciplinary approach, "Management of patients treated with idelalisib" (Pesaro, Italy)
2017	20 apr: "Treatment and clinical management of Acute Myeloid Leukemia in elderly" (Senigallia, Italy)
2017	01 mar: Next in Leukemia investigator's meeting (Milan, Italy)

2016	28 oct: New acquisitions in Hematology: from diagnosis to clinical case to therapy (Tivoli, Italy)
2016	24 may: Follicular Lymphoma and CLL, "Hard to treat follicular lymphoma" (San Benedetto del Tronto, Italy)
2016	08 feb: Preceptorship MDS Masterclass "Diagnosis of MDS" (Pesaro, Italy)
2016	08 feb: Preceptorship MDS Masterclass "Transfusions and iron chelation: when and how?" (Pesaro, Italy)
2015	13 nov: competitor at Under40 in Hematology "Low dose lenalidomide and cytarabine combo produces an high complete remission rate that can be predicted by genetic profiling in AML patients aged >=70 years: final results of a phase II study" (Verona, Italy)
2015	04-07 oct: selected abstract for poster presentation at 45° SIE "Benda-BEAM high dose therapy prior to auto-SCT is effective in resistant/relapsed DLBCL: a phase II multicenter study" (Florence, Italy)
2014	04 jul: "MDS-Day" (Bologna, Italy)
2014	15-17 oct: selected abstract for poster presentation at XIII SIES "Azacitidine in high risk myelodysplastic syndromes: retrospective analysis of 28 patients treated with the aza 5-2-5 regimen" (Rimini, Italy)
2013	14-15 nov: invited speaker at Under 40th in Hematology 2013 "Future in the treatment of oncohematologic diseases: myelodysplastic syndromes" (Turin, Italy)
2013	20-23 oct: selected abstract for poster presentation at 44° SIE "Azacitidine in high and low risk myelodysplastic syndromes: retrospective evaluation of 57 patient treated with 4 different therapeutic regimens" (Verona, Italy)
2013	04 jul: "Iron chelation therapy in hematologic transfusion-dependent patients" Panel discussion (Bologna, Italy)
2013	24 jun: "Rapid fire in hematology: clinical experiences compared on myelodysplastic syndromes and acute myeloid leukemia" (Mogliano Veneto, Italy)
2013	13-16 jun: selected abstract for poster presentation at 18° EHA Congress "Prolonged low dose azacitidine schedule in high risk MDS patients: long term efficacy and relationship with molecular response" (Stockholm, Sweden)
2013	28 may: "Bridge: bridging research and clinical experience in MDS/AML", (Padova, Italy)
2013	14 feb: "Myelodysplastic syndromes: what is the cure today?" (Bologna, Italy)
2012	22 nov: "Clinical experience with Lenalidomide in MDS" (Zurich, Switzerland)
2012	17-19 oct: selected abstract for poster presentation at XII SIE "Azacitidine in myelodysplastic syndromes retrospective evaluation of long-responder patients" (Rome, Italy)
2012	18 may: "Rapid fire in Hematology: clinical experiences compared on Myelodysplastic Syndromes and Acute Myeloid Leukemia" (Reggio Emilia, Italy)
2011	03 dic: "Anemia in elderly patient: diagnostic pathway and therapeutic approach" (Bologna, Italy)



2011	05 nov: meeting Sabato Ematologico della Romagna "5-azacitidine: questions?" (Faenza, Italy)
2011	16-19 oct: selected abstract for poster presentation at 43° SIE "Iron overload and iron chelation therapy in myelodysplastic syndromes and in other trasnfusion-dependent chronic anemias. Retrospective study of 45 patients" (Naples, Italy)
2011	28 apr: "Therapy with azacitidine: management of adverse events" at the congress "MDS doc: best practice in the treatment with hypomethylating agents" (Modena, Italy)
2011	22 mar: "PNH and thrombosis" at the Congress "Paroxistic nocturnal hemoglobinuria: latest developments in diagnosis and treatment" (Bologna, Italy)
2010	06 oct: selected abstract for Oral presentation at XI SIE "Azacitidine for the treatment of high and low risk myelodysplastic syndromes. Hematologic and molecular response to 2 alternative dosing schedules" (Turin, Italy)
2010	12 jun: selected abstract for poster presentation at 15° EHA Congress "Valproic Acid and Azacitidine Combinatorial Effect on Phosphoinositide-phospholipase C (PI-PLC)beta1 and Cyclin D3 in High Risk Myelodysplastic Syndromes" (Barcelona, Spain)
2010	12 jun: selected abstract for poster presentation at 15° EHA Congress "Effect of alternative dosing schedules of azacitidine on phosphoinositide-phospholipaseC-beta1 in high risk MDS patients" (Barcelona, Spain)
2010	26 may: National Congress of SIFO (Italian Society of Hospital Pharmacy) "Myelodysplastic Syndromes: therapy today" (Bologna, Italy)
2010	18 may: National Congress of FADOI (Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti) "When to suspect a Myelodysplastic Syndrome" (Bologna, Italy)
2010	29 apr: National Congress MDS expert meeting "Interactive clinical case: MDS/MPN" (Rome, Italy)
2009	18-21 oct: selected abstract for poster presentation at 42° SIE "Iron overload and iron chelation therapy in myelodysplastic syndromes and in other trasnfusion-dependent chronic anemias. Retrospective study of 45 patients" (Milan, Italy)
2009	18-21 oct: selected abstract for poster presentation at 42° SIE "Azacitidine in high risk and low risk myelodysplastic syndromes. Retrospective evaluation of 4 different therapeutic regimens" (Milan, Italy)
2008	20 mar: "MDS/AZA0706 clinical and biological effects of 5-azacitidine 5 days/monthly schedule in symptomatic low-risk myelodysplastic syndrome" (Bologna, Italy)

PREMI	
2008	Winner of the Italian Society of Experimental Hematology Clinical Research Grant, awarded during the 10 <sup>th</sup> SIES Congress in Bari (Italy) for the project "PI-PLC-BETA-1 monoallelic deletion in myelodisplastic syndromes". Clissa C, Mongiorgi S, Follo MY, Finelli C, Bosi C, Martinelli G, Baccarani M, Martelli AM, Cocco L.

EVENTI FORMATIVI	
21-22/09/2021	Boot Camp Multiple Myeloma Padova (Italy)



16/09/2021	ITP anniversary revolution (webinar)
8-11/09/2021	IMWG International Myeloma Working Group 2021 (Vienna)
27/04/2021	Il GDPR e la protezione dei dati sanitari in azienda (Verona)
3-6/03/2021	European Myeloma Network (EMN) 2021 (webinar)
26-28/10/2020	Nuove sfide in Ematologia (Pesaro, webinar)
23/09/2020	Covid-19 dalla diagnosi alla terapia con plasma iperimmune (webinar)
18/09/2020	Cosa c'è di nuovo nel trattamento della LLC (webinar)
16/09/2020	Ironoverload in Myelofibrosis (webinar)
14-15/09/2020	Terapie personalizzate nelle neoplasie mieloidi (webinar)
10/09/2020	MKC academy (webinar)
28-30/10/2019	Stage Haematology 2019 (Pesaro, Italy)
09/07/2019	Quali novità in ITP (Ancona, Italy)
09-11/05/2019	AML Rising Star Program (Windsor, London, UK)
10-12/04/2019	5° Corso di Alta Formazione in Emostasi e Trombosi (Palermo, Italy)
04-05/04/2019	Iberia&Italy stand-alone on CML "beyond the frontline, never ever give up" (Valencia, Spain)
30/11/2018	Connect: stewardship antimicrobica, Pesaro (Italy)
18-20/10/2018	XV Congress of SIES (Rimini, Italy)
26-28/04/2018	6 <sup>th</sup> International Conference on Myelodysplastic Syndromes (Mandelieu, France)
15-18/10/2017	46° Congress of SIE (Rome, Italy)
21/09/2017	Myelofibrosis and polycythemia vera: new therapeutic options and clinical management of patients (Pesaro, Italy)
03-06/05/2017	14 <sup>th</sup> International Symposium on Myelodysplastic Syndromes (Valencia, Spain)
27/04/2017	PNH masters Program (Paris, France)
11/04/2017	Certification course for Search Coordinator GITMO/IBMDR (Milan, Italy)
31/03-01/04/2017	8 <sup>th</sup> Celgene Investigator Research meeting (Saronno, Italy)
10-11/03/2017	Expert forum. Rethinking approaches to B-cell malignancies (London, UK)
26-27/01/2017	Thrombotic microangiopathy forum (Barcelona, Spain)
19-21/10/2016	XIV Congress of SIES (Rimini, Italy)
28/09-04/10/2016	Sistema di accreditamento JACIE Hematology and Stem Cell Transplant Center Pesaro (Pesaro, Italy)
21-22/09/2016	PNH meet the expert (Milan, Italy)
09-11/05/2016	New drugs in Hematology (Bologna, Italy)
27/04/2016	Basic Life Support (Pesaro, Italy)
02-04/11/2015	Stage "Hematology in 2015: how music is changing?" (Pesaro, Italy)
04-07/10/2015	45° Congress of SIE (Florence, Italy)
28/05/2015	Face OFF - Il tempo del confronto (Fano Italy)
22/05/2015	The cellular therapies (Pesaro, Italy)
29/4-2/5/2015	13 <sup>TH</sup> International Symposium on Myelodysplastic Syndromes (Washington DC)
17-18/03/2015	HEMA Excellence Comunicazione efficace in ematologia (Rome, Italy)
28/11/2014	Advisory Board on Bendamustine in Multiple Myeloma (Bologna, Italy)
03-05/11/2014	Stage Innovations in Hematology (Pesaro, Italy)
15-17/10/2014	XIII Congress of SIES (Rimini, Italy)
12-15/06/2014	19th Congress of EHA (Milan, Italy)
15-17/05/2014	The 4th International Conference on Myelodysplastic Syndromes (Estoril, Portugal)
13/05/2014	AZA_MDS-003 & CC-486-AML-001 Investigator Meeting (Bologna, Italy)
28/03/2014	The PNH Meet the expert (London, UK)
07-08 /03/2014	5th Investigator Research Meeting (Munich, Germany)
28/02-1/03/2014	Clinical trails and young investigators: hit the target (Rome, Italy)



19/02/2014	Clinical trails and young investigators: hit the target (Pisa, Italia)
20-23/10/2013	44° Congress of SIE (Verona, Italy)
13-16/06/2013	18th Congress of EHA (Stockholm, Sweden)
08-11/05/2013	The 12th International symposium on myelodysplastic syndromes (Berlin, Germany)
27-28/10/2012	ESH-EHA 26th type1 hematology tutorial on diagnostic work-up of hematological malignancies focus syndromes (Lisbon, Portugal)
17-19/10/2012	XII Congress of SIES (Rome, Italy)
14-17/06/2012	The 17th Congress of EHA (Amsterdam, Netherlands)
11/05/2012	Next generation siquencing: new goals for diagnostics and personalized leukemia therapies (Bologna, Italy)
15-17/03/2012	New Drugs for leukemia (Genova, Italy)
03/03/2012	Dasatinib: innovation in leukemia Ph+ management (Bologna, Italy)
9-10/02/2012	Ontime Investigator's meeting (Barcelona, Spain)
20-21/01/2012	Therapeutic advances, drugeconomy and evidence based medicine (Bologna, Italy)
05/11/2011	Sabato ematologico della Romagna (Faenza, Italy)
16-19/10/2011	43° Congress of SIE (Naples, Italy)
9-12/06/2011	The 16th Congress of EHA (London, United Kingdom)
18-21/05/2011	The 11th International symposium on myelodysplastic syndromes (Edinburgh, Scotland)
12/05/2011	Updates in antifungal therapy: the word to the experts (Bologna, Italy)
28/04/2011	MDS doc: best practice in the treatment with hypomethylating agents (Modena, Italy)
22/03/2011	Paroxysmal nocturnal hemoglobinuria: news in diagnosis and treatment (Bologna, Italy)
12-13/03/2011	Global Iron Summit, GIS (Istanbul, Turkey)
6-8/10/2010	XI Congress of SIES (Turin, Italy)
20-22/09/2010	Corso residenziale di patologia clonale e immuno-mediata dell'emopoiesi (Florence, Italy)
21-23/06/2010	Stage Thrombocytopenias (Bologna, Italy)
10-13/06/2010	The 15th Congress of EHA (Barcelona, Spain)
27/03/2010	Sabato ematologico della Romagna (Ravenna, Italy)
18/03/2010	Discutiamone insieme (Florence, Italy)
18-19/02/2010	ESCMID conference: Invasive fungal infections (Rome, Italy)
20-21/11/2009	Immunity and hemopoietic stem cells transplant ation (Corciano, Italy)
09/10/2009	Training ALCOA, GCP; SAE and management of experimental drug (Bologna, Italy)
10/10/2009	Sabato ematologico della Romagna (Rimini, Italy)
18-21/10/2009	42° Congress of SIE (Milan, Italy)
28/09/2009	From biology of leukemic cell to new therapeutic approach (Bologna, Italy)
26/09/2009	Sabato ematologico della Romagna (Meldola, Italy)
13/06/2009	Sabato ematologico della Romagna (Faenza, Italy)
06-09/04/2009	The 10th International symposium on myelodysplastic syndromes (Patras, Greece)
20-22/04/2009	MDS: biology, pathophysiology, clinical and new therapeutic perspectives (Bologna, Italy)
06-09/12/2008	The 50th Annual meeting ASH (San Francisco, California)
21/11/2008	National project: top seminar in allogenic stem cells transplantation. Fungal infections in allogenic stem cells transplantation. State of art (Bologna, Italy)
31/10/2008	MDS colloquium (Berlin, Germany)
15-17/10/2008	PNH masters programme WORKSHOP (St.James Universitary Hospital Leeds,UK)
05-07/10/2008	New drugs in Hematology (Bologna,Italy)
24-26/09/2008	X Congress of SIES (Bari, Italy)
10/03/2008	Guidelines SIE, SIES, GITMO for the treatment of acute myeloid leukemias (Bologna,Italy)

29-31/10/2007	Stage: iron chelation (Bologna, Italy)
14-17/10/2007	41° Congress of SIE (Bologna, Italy)
10-12/09/2007	Stage Myelodysplastic syndromes: from theory to practice (Bologna, Italy)
17-21/09/2007	Stage Chronic Lymphatic Leukemia (Bologna, Italy)
16/11/2006	Hodgkin Lymphoma: current events and perspectives (Pescara, Italy)

Il Sottoscritto è consapevole della responsabilità penale cui può andare incontro in caso di dichiarazione mendace, ai sensi dell'art. 76 del D.P.R. 445 del 28/12/2000" e autorizza il trattamento dei propri dati personali presenti nel CV ai sensi dell'art. 13 del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e dell'art. 13 del GDPR (Regolamento UE 2016/679); autorizza inoltre la pubblicazione nella banca dati dell'area tematica ECM del portale della Regione del Veneto.

Verona, 03/07/2022

Cristina Clissa

